teniloxazine

{{Drugbox | Verifiedfields = changed | verifiedrevid = 470601949 | IUPAC_name = 2-{[2-(thiophen-2-ylmethyl)phenoxy]methyl}morpholine | image = Teniloxazine.svg | image_class = skin-invert-image | width = 215 | CAS_number_Ref = | CAS_number = 62473-79-4 | CAS_supplemental = 62473-80-7 (maleate) | ATC_prefix = None | ATC_suffix = | UNII_Ref = | UNII = 95Q6WNP25P | PubChem = 119114 | ChemSpiderID = 106426 | ChemSpiderID_Ref = | ChEMBL = 2105438 | C = 16 | H = 19 | N = 1 | O = 2 | S = 1 | smiles = O1CCNCC1COc2ccccc2Cc3sccc3 | synonyms = Y-8894 | StdInChI_Ref = | StdInChI = 1S/C16H19NO2S/c1-2-6-16(19-12-14-11-17-7-8-18-14)13(4-1)10-15-5-3-9-20-15/h1-6,9,14,17H,7-8,10-12H2 | StdInChIKey_Ref = | StdInChIKey = OILWWIVKIDXCIB-UHFFFAOYSA-N | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_category = | legal_status = Rx-only | routes_of_administration = Oral }}

Teniloxazine (Lucelan, Metatone), also known as sufoxazine and sulfoxazine, is a drug which is marketed in Japan. Though initially investigated as a neuroprotective and nootropic agent for the treatment of cerebrovascular insufficiency in the 1980s, it was ultimately developed and approved as an antidepressant instead. It acts as a potent norepinephrine reuptake inhibitor, with fair selectivity over the serotonin and dopamine transporters, and also behaves as an antagonist of the 5-HT2A receptor.